Achillion Pharmaceuticals Competitors and Similar CompaniesClear all
Achillion Pharmaceuticals's competitors and similar companies include UCB, CSL Behring, Biogen and Chiesi Group.
 Achillion Pharmaceuticals Achillion Pharmaceuticals is a company engaged in the discovery, development and commercialization of treatments for infectious diseases. |  UCB UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions. |  Biogen Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases. |  Chiesi Group Chiesi Group (Gruppo Chiesi, also known as CHIESI Farmaceutici) is a company that researches, develops, produces, and commercializes therapeutic solutions. | ||
Founding Date | Founding Date 1998 | Founding Date 1928 | Founding Date 1904 | Founding Date 1978 | Founding Date 1935 |
Type | Type Public | Type Public | Type Subsidiary | Type Public | Type Subsidiary |
Tags | |||||
Locations | Locations New Haven, US HQ Blue Bell, US | Locations Brussels, BE HQ Melbourne, AU Vienna, AT Braine L'alleud, BE Braine L'alleud, BE Leuven, BE São Paulo, BR see more | Locations King of Prussia, US HQ Broadmeadows, AU Parkville, AU Parkville, AU Wien, AT Mechelen, BE see more | Locations Cambridge, US HQ Vicente López, AR Macquarie Park, AU Wien, AT Machelen, BE São Paul, BR Toronto, CA see more | Locations Parma, IT HQ Melbourne, AU Wien, AT Machelen, BE Santana De Parnaíba, BR São Paulo, BR Sofia, BG see more |
Employees | Employees 5636% decrease | Employees 9,052 | Employees 7,5692% decrease | Employees 7,605 | Employees 5,8541% increase |
Valuation ($) | Valuation ($) 23.7 m | Valuation ($) 34.3 b | Valuation ($) N/A | Valuation ($) 26.7 b | Valuation ($) N/A |
Financial | |||||
Revenue (est.) | Revenue (est.) N/A | Revenue (est.) €7.4b (FY, 2025) | Revenue (est.) $7.9b (FY, 2020) | Revenue (est.) $9.9b (FY, 2025) | Revenue (est.) €2.4b (Y, 2021) |
Cost of goods | Cost of goods N/A | Cost of goods €1.4b (FY, 2025) | Cost of goods N/A | Cost of goods $2.4b (FY, 2025) | Cost of goods N/A |
Gross profit | Gross profit N/A | Gross profit €7.2b (FY, 2025) | Gross profit $4.5b (FY, 2020) | Gross profit $7.5b (FY, 2025) | Gross profit N/A |
Net income | Net income ($70.3m) (FY, 2018) | Net income €1.6b (FY, 2025) | Net income N/A | Net income $1.3b (FY, 2025) | Net income N/A |
Operating ⚠ | |||||
Countries | Countries N/A | Countries 35 (FY, 2019) | Countries 100 (Dec, 2020) | Countries N/A | Countries N/A |
For sources of this data, please see the company profile
View Company Profiles
UCB
HQ
Brussels, BE
Employees
9,052
UCB is a company that provides biopharmaceutical research and development solutions for neurological and immunological conditions.
View companyBiogen
HQ
Cambridge, US
Employees
7,605
Biogen (formerly known as Biogen Idec) is a biopharmaceutical company that develops and delivers therapies for neurological and neurodegenerative diseases.
View companyChiesi Group
HQ
Parma, IT
Chiesi Group (Gruppo Chiesi, also known as CHIESI Farmaceutici) is a company that researches, develops, produces, and commercializes therapeutic solutions.
View company